NCT03221400
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Patients with leptomeningeal disease or symptomatic brain metastases that require treatment
https://ClinicalTrials.gov/show/NCT03221400